NOVELIX.BO · BSE
NOVELIX PHARMACEUTICALS LIMITE
₹72.52
-2.19% (-₹1.62)
Prev. close
₹74.14
Volume
11,527
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About NOVELIX PHARMACEUTICALS LIMITE
Novelix Pharmaceuticals Limited trades in pharmaceuticals and related products in India. It also trades in shares and securities; retails pharmaceuticals; and offers marketing services. The company was formerly known as Trimurthi Limited and changed its name to Novelix Pharmaceuticals Limited in October 2024. Novelix Pharmaceuticals Limited was incorporated in 1994 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Venkateshwarlu Pulluru
Headquarters
Hyderabad
Employees
32
Website
novelixpharma.comExchange
View on BSE ↗Key stats
Market cap
₹206.46 Cr
P/E ratio (TTM)
45.0
EPS (TTM)
₹1.61
Beta (1Y · daily vs NIFTY 50)
0.47
Beta (5Y · monthly vs NIFTY 50)
0.60
Shares float
65.78 L
EPS · quarter ended Jun 2026
₹0.49
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹98.80 L | — | ₹1.41 Cr | ₹4.22 Cr | ₹30.72 Cr | ₹132.31 Cr | |
| EBITDA | — | — | ₹-51.77 L | ₹6.04 L | ₹16.10 L | ₹3.51 Cr |
| ₹-3.27 Cr | — | ₹-6.00 L | ₹1.04 L | ₹8.40 L | ₹2.56 Cr | |
| Diluted EPS | ₹-4.04 | — | ₹-0.07 | — | ₹0.09 | ₹1.21 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹7.26 Cr | ₹7.36 Cr | ₹27.21 Cr | ₹92.42 Cr | |
| — | ₹16.45 L | — | — | ₹0 | ₹4.32 Cr | |
| Stockholders' equity | — | — | ₹7.20 Cr | ₹7.35 Cr | ₹17.54 Cr | ₹46.49 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-2.41 Cr | ₹-34.35 L | ₹-13.68 Cr | ₹-22.39 Cr | |
| Investing cash flow | — | — | ₹7.51 L | ₹18.65 L | ₹2.93 Cr | ₹-1.72 Cr |
| Financing cash flow | — | ₹0 | — | ₹0 | ₹11.32 Cr | ₹26.39 Cr |
| Capital expenditure | — | ₹-1.86 Cr | ₹-43,790 | — | ₹-10.61 L | ₹-3.26 Cr |
| End cash position | — | — | ₹27.47 L | ₹11.79 L | ₹67.86 L | ₹2.96 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| NOVELIX PHARMACEUTICALS LIMITE | ₹220.64 Cr | ₹77.5 | 48.1 | 4.75 | 5.5% | 0.09 | +330.7% | +93.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 17
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.